Alnylam Pharmaceuticals | ALNY - Eps Gewinn Pro Aktie

Aktienkurs
294.40
Täglich Wechseln
8.13 2.84%
Monatlich
-5.32%
Jährlich
0.93%
Q2 Prognose
281.21

Fiscal Kalender Aktuell Konsens Zuletzt Datum
FY2026Q1 Mar/2026 1.99 0.99 -0.01 Apr/30
FY2025Q4 Dec/2025 1.25 1.27 0.06 Feb/12
FY2025Q3 Sep/2025 2.90 0.27 -0.50 Oct/30
FY2025Q2 Jun/2025 0.32 -0.73 0.56 Jul/31
FY2025Q1 Mar/2025 -0.01 -0.94 -0.16 May/01




Eps Veränderung Datum
Acadia Pharmaceuticals USD 0.02 1.58 2026-03
Agios Pharmaceuticals USD -1.69 0.17 2026-03
Alnylam Pharmaceuticals USD 1.99 0.74 2026-03
Amgen USD 5.15 0.14 2026-03
Arrowhead Research USD -0.93 1.15 2026-03
BioCryst Pharmaceuticals USD 1.17 1.1 2025-12
BioMarin Pharmaceutical USD 0.76 0.3 2026-03
Incyte USD 1.81 0.01 2026-03
Ionis Pharmaceuticals USD -0.56 0.85 2026-03
Moderna USD -3.4 1.29 2026-03
Neurocrine Biosciences USD 1.94 0.06 2026-03
Novartis USD 1.99 0.45 2026-03
PTC Therapeutics USD -0.03 1.64 2026-03
Regeneron Pharmaceuticals USD 9.47 1.97 2026-03
Sangamo BioSciences USD -0.18 0.1 2024-06
Sanofi EUR 2.17 2.84 2026-03
Sarepta Therapeutics USD 3.16 6.74 2026-03
Takeda JPY -15.56 81.3 2026-03
Tectonic Therapeutic USD -1.03 0.01 2025-12
Ultragenyx Pharmaceutical USD -1.84 0.55 2026-03
Vertex Pharmaceuticals USD 4.47 0.56 2026-03
Xencor USD -1.71 1.62 2026-03